TW EN

scroll

Go Top

臺北榮民總醫院 新藥臨床試驗中心Taipei Veterans General Hospital General Clinical Research Center

  • Total Beds2,802
  • Total Doctors1,416
  • AddressNo.201, Sec. 2, Shipai Rd.,Beitou,Taipei City 112
  • Emailgcrc@vghtpe.gov.tw

1. The headquarter of cardiovascular metabolic consortium in Taiwan

2. A hub of rare disease trial in Taiwan

3. A stem cell research headquarter in Taiwan

Site Introduction

10 reasons for conducting clinical trials in TVGH:
(1) Leading medical center in Taiwan (2) Largest patient pool (3) A dedicated area of 3000 m2 (4) Discipline and united (5) Strong leadership (6) Dedicated faculty member (7) Efficient IRB (8) Rapidity in contracting (9) Leading role in clinical trial network in Taiwan (10) Reputation of TVGH

Clinicl Trial Expertise

Cardiology, Endocrinology, Metabolism, Oncology, Gastroenterology, Hepatology, Hematology, Immunology, Rheumatology , Nephrology, Infectious Disease, Toxicology, Orthopedics, Chest, Pediatrics, Rehabilitation, Radiology, Neurology, Neurosurgery, Psychiatry, Emergency Medicine, Dentistry, Ophthalmology, Dermatology, Chinese Medicine, Anesthesiology, Thoracic Surgery, Cardiovascular Surgery, Colon & Rectal Surgery, Plastic & Reconstructive Surgery, Pediatric Surgery, Urology, Gynecology, Obstetrics and Pregnancy Otolaryngology

International Accreditation

FERCAP, AAHRPP, CAP

GCP Inspection/audit

US FDA, EMA

What types of clinical trial do you conduct?

Spotlights

CTC

Publications

CTC

1

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., . . . Sabatine, M. S. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 380(4), 347-357. doi:10.1056/NEJMoa1812389

2

Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., . . . Zeiher, A. M. (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 379(22), 2097-2107. doi:10.1056/NEJMoa1801174

3

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., . . . Inzucchi, S. E. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373(22), 2117-2128. doi:10.1056/NEJMoa1504720

4

Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., . . . Heineman, T. C. (2015). Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. New England Journal of Medicine, 372(22), 2087-2096. doi:10.1056/NEJMoa1501184

5

Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., . . . Antman, E. M. (2013). Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 369(22), 2093-2104. doi:10.1056/NEJMoa1310907

6

Hokusai-VTE Investigators, B. H., Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. (2013). Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. New England Journal of Medicine, 369(15), 1406-1415. doi:10.1056/NEJMoa1306638